Last updated on February 2019

Dose Finding Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis


Brief description of study

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.

Clinical Study Identifier: NCT02770170

Contact Investigators or Research Sites near you

Start Over

Boehringer Ingelheim Call Center

Prince of Wales Hospital
HK, Hong Kong
  Connect »

Boehringer Ingelheim Call Center

Queen Mary Hospital
Hong Kong, Hong Kong
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.